Lexeo Therapeutics (LXEO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Voting matters and shareholder proposals
Election of Paula HJ Cholmondeley, Brenda Cooperstone, and R. Nolan Townsend as Class III directors is proposed, with board recommendation to vote in favor.
Ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is recommended.
Proxyholders are authorized to vote on any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Three nominees are presented for election as Class III directors, indicating a staggered board structure.
Audit committee and external auditor matters
KPMG LLP is proposed for ratification as the independent auditor for the next fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lexeo Therapeutics
- Directors and auditor ratified; no stockholder questions submitted.LXEO
AGM 202625 Jun 2026 - Gene therapies for rare cardiac diseases advance with strong clinical data and key milestones ahead.LXEO
Corporate presentation16 Jun 2026 - Pivotal LX2006 trial in FA set for Q2 2026, targeting accelerated approval and BLA in 2028.LXEO
Investor update15 Jun 2026 - Pivotal gene therapy studies advance with robust efficacy, regulatory progress, and strong safety data.LXEO
RBC Capital Markets Global Healthcare Conference 202622 May 2026 - Gene therapies for rare cardiac diseases show strong clinical progress and 2026 milestones ahead.LXEO
Corporate presentation11 May 2026 - LX2006 pivotal trial advances, strong cash runway, and reduced net loss highlight Q1 2026.LXEO
Q1 202611 May 2026 - Annual meeting to elect directors, ratify auditor, and reinforce governance and shareholder rights.LXEO
Proxy filing30 Apr 2026 - Gene therapies show robust efficacy and safety in FA and PKP2-ACM, with pivotal trials ahead.LXEO
Oppenheimer 36th Annual Healthcare Life Sciences Conference7 Apr 2026 - Gene therapies for rare cardiac diseases show strong clinical progress and pivotal trials ahead.LXEO
Corporate presentation30 Mar 2026